CytomX醫療 CTMX 深 滬
已收盤 12-24 16:00:00 美东时间
4.40
+0.200
+4.76%
華盛通- 最 高4.455
- 今 開4.19
- 成交量 145.76万股
- 最 低 4.12
- 昨 收 4.20
- 總市值 7.26亿
- 52周最高 4.62
- 市盈率 靜 11.70
- 換手率 0.88%
- 52周最低 0.40
- 委 比 -76.57%
- 總股本 1.65亿
- 歷史最高 35.00
- 量 比 0.24
- 振 幅 7.98%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
12-18 21:04
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
Vera Therapeutics宣布任命James R. Meyers为其董事会成员。Meyers拥有超过30年的生物制药行业商业领导经验，曾任职于Gilead Sciences和BCG。Vera Therapeutics专注于开发免疫疾病治疗方法，其主要候选药物Atacicept是一种双重BAFF/APRIL抑制剂，用于治疗IgA肾病和其他自身免疫性疾病。公司计划明年推出该药物，并继续在其他疾病领域开发其潜力。
11-26 21:05
CytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on December 2 in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, NY. Both events will feature fireside chats and live webcasts available on CytomX’s website. The company, focused on developing conditionally activated biologics for oncolog...
11-25 13:00
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
CytomX Therapeutics' CEO, Sean McCarthy, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 20, 2025. A live webcast of the presentation will be available on CytomX's website, and management will also hold one-on-one meetings with registered investors. CytomX is focused on developing conditionally activated biologics for cancer treatment, utilizing its PROBODY® therapeutic platform to create lo...
11-13 13:00
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
CytomX Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
CytomX Therapeutics shares are trading lower after the company reported worse-t...
11-07 06:20
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics, a leader in conditionally activated biologics, will announce its third-quarter 2025 financial results on November 6 after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m. PT. Access the webcast via CytomX’s website or register beforehand. The company, focused on localized cancer therapies, features a PROBODY platform with candidates like CX-2051 and CX-801. For more info, contact Chris...
10-30 12:00
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
During the last three months, 4 analysts shared their evaluations of CytomX The...
10-22 05:01
